Company intelligence / Profile preview

Mana.bio

Tel Aviv, Tel Aviv District, Israel

Ownership: Private
Development stage: Preclinical

Overview

Mana.bio has demonstrated rapid in vivo delivery to multiple extrahepatic organs and cell types using its proprietary AI-driven LNP platform. The company reports broad improvements in systemic tolerability while maintaining potency/specificity, but no clinical trial results have been published yet. Their approach aims to accelerate the development of safe, effective RNA/gene therapies by overcoming traditional bottlenecks in drug delivery.

Therapeutic areas: Other
Modalities: mRNA-based therapeuticsOligonucleotide therapiesGene therapyVaccinesRNA-based therapeutics
Industry: Biotech

Drug pipeline

1 asset

FMB-3991

Preclinical

Partnerships

Open to collaborations with pharma/biotech partners; specific partnerships not disclosed as of May 2025.

Beyond the preview

Go deeper on Mana.bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mana.bio.

Explore the full profile